Antigen Suppression Over Time Mitigates Clonal Evolution of Plasma Cells in Gaucher Disease
By
Noor Ul Ain
Noffar Bar
Lilu Guo
Katherine Klinger
Punita Gupta
Atta Ur Rahman
Ruhua Yang
Yanhong Deng
Natalia Neparidze
Shiny Nair
Pramod K. Mistry
June 17, 2026
Clinical Scorecard: Antigen Suppression Over Time Mitigates Clonal Evolution of Plasma Cells in Gaucher Disease
At a Glance
Category Detail
Condition Gaucher Disease Key Mechanisms Chronic antigenic stimulation linked to clonal plasma cell evolution. Target Population Adult patients with Gaucher disease. Care Setting Tertiary referral center.
Key Highlights
Gaucher disease is linked to clonal plasma cell expansion. LysoGL1 is a key biomarker and antigenic target in Gaucher disease. GD-specific therapy reduces LysoGL1 levels and clonal immunoglobulin levels. Cumulative therapy may reduce the risk of developing monoclonal gammopathy. Study design focused on incident cases of clonal plasma cell disorders. Guideline-Based Recommendations
Diagnosis
Confirmed Gaucher disease based on reduced leukocyte acid β-glucosidase activity and biallelic pathogenic variants in GBA1. Management
GD-specific therapy includes enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Monitoring & Follow-up
Regular clinical evaluations and serum protein studies every 6–12 months. Risks
Sustained antigenic stimulation may drive progression to monoclonal gammopathy. Patient & Prescribing Data
Adults with Gaucher disease without pre-existing monoclonal gammopathy.
Treatment decisions were based on systemic GD manifestations, not on clonal plasma cell findings.
Clinical Best Practices
Conduct longitudinal follow-up to monitor for incident clonal plasma cell disorders. Utilize standardized diagnostic criteria for monoclonal gammopathy. Related Resources & Content
